KL

Kishori Lal Gupta

Director Director DIN 00303636
DIN 00303636 First appointment Aug 2005 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Aug 2005
Shareholding value •••• Premium profile

About Kishori Lal Gupta

Data last updated:

Kishori Lal Gupta was a Director at Mks Pharma Limited (2005–2016) and Director at Skymap Pharmaceuticals Private Limited (2006–2016). The companies operate in Pharma.

DIN 00303636
Primary Designation Director
Industry Pharma
First Appointment 01 Aug 2005

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Mks Pharma Limited U24232DL2005PLC139202
Director01 Aug 20052005₹27.73 Cr (FY 2017)Amalgamated
Director24 Jun 20062006₹409 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Mks Pharma Limited
Skymap Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Kishori Lal Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kishori Lal Gupta

Kishori Lal Gupta was first appointed on 01 Aug 2005 as Director at Mks Pharma Limited. The most recent appointment on record is 24 Jun 2006 at Skymap Pharmaceuticals Private Limited.

Kishori Lal Gupta held 2 earlier board appointments: Mks Pharma Limited (Director, 01 Aug 2005 to 30 Aug 2016); Skymap Pharmaceuticals Private Limited (Director, 24 Jun 2006 to 09 Oct 2016).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available